Advertisement

Lobectomy Versus Total Thyroidectomy in Suspicious or Malignant Thyroid Nodules

  • Jennifer S. MammenEmail author
  • David S. Cooper
Chapter
  • 33 Downloads

Abstract

Differentiated thyroid cancer frequently has an excellent prognosis, with very low risk of recurrence after adequate surgery. A growing body of evidence demonstrates no benefit from radioactive iodine or extensive surgery in these low-risk patients and suggests that many individuals will be well treated with less than total thyroidectomy. Determining the best initial surgery to minimize complications but also avoid reoperation is a critical goal of the preoperative assessment. Accurate assessment is particularly valuable with transoral surgery, where conversion to open procedures for unexpected intraoperative findings and reoperation both present challenges. Ultrasound findings and patient characteristics are variably helpful in predicting postoperative risk status. The development of strategies to determine the best surgical approach in individual patients has been a main focus of the American Thyroid Association guidelines, which now recommend lobectomy be considered for solitary nodules up to 4 cm without evidence of extrathyroidal extension on ultrasound. The cost-effectiveness of this or other paradigms for predicting risk remains an active area of research.

Keywords

Differentiated thyroid cancer Lobectomy Total thyroidectomy Recurrence Low risk Ultrasound Pathology Age Cancer staging Cost-effectiveness 

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Brito JP, Hay ID, Morris JC. Low risk papillary thyroid cancer. BMJ. 2014;348:g3045.CrossRefGoogle Scholar
  3. 3.
    Ahn HS, Kim HJ, Kim KH, et al. Thyroid cancer screening in South Korea increases detection of papillary cancers with no impact on other subtypes or thyroid cancer mortality. Thyroid. 2016;26:1535–40.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    McLeod DS, Cooper DS, Ladenson PW, et al. Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. Thyroid. 2014;24:35–42.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Razavi CR, Russell JO. Indications and contraindications to transoral thyroidectomy. Ann Thyroid. 2017;2  https://doi.org/10.21037/aot.2017.10.01. Epub 2017 Oct 31.
  6. 6.
    Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26:879–85.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Nixon IJ, Wang LY, Migliacci JC, et al. An international multi-institutional validation of age 55 years as a cutoff for risk stratification in the AJCC/UICC staging system for well-differentiated thyroid cancer. Thyroid. 2016;26:373–80.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Lamartina L, Grani G, Arvat E, et al. 8th edition of AJCC/TNM staging system of thyroid cancer: what to expect. Endocr Relat Cancer. 2017;25:L7–L11.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Durante C, Montesano T, Torlontano M, et al. Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. J Clin Endocrinol Metab. 2013;98:636–42.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–214.CrossRefGoogle Scholar
  12. 12.
    Shi X, Liu R, Basolo F, et al. Differential clinicopathological risk and prognosis of major papillary thyroid cancer variants. J Clin Endocrinol Metab. 2016;101:264–74.CrossRefGoogle Scholar
  13. 13.
    Wreesmann VB, Nixon IJ, Rivera M, et al. Prognostic value of vascular invasion in well-differentiated papillary thyroid carcinoma. Thyroid. 2015;25:503–8.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Ganly I, Wang L, Tuttle RM, et al. Invasion rather than nuclear features correlates with outcome in encapsulated follicular tumors: further evidence for the reclassification of the encapsulated papillary thyroid carcinoma follicular variant. Hum Pathol. 2015;46:657–64.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2:1023.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Youngwirth LM, Adam MA, Scheri RP, et al. Extrathyroidal extension is associated with compromised survival in patients with thyroid cancer. Thyroid. 2017;27:626–31.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Tuttle M, Morris LF, Haugen B, Shah J, Sosa JA, Rohren E, Subramaniam RM, Hunt JL, Perrier ND. Thyroid-differentiated and anaplastic carcinoma. In: Amin MB, Edge SB, Greene F, Byrd D, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley J, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR, editors. AJCC cancer staging manual. 8th ed. New York: Springer; 2017.Google Scholar
  18. 18.
    Wang LY, Ghossein R, Palmer FL, et al. Microscopic positive margins in differentiated thyroid cancer is not an independent predictor of local failure. Thyroid. 2015;25:993–8.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Kluijfhout WP, Pasternak JD, Kwon JS, et al. Microscopic positive tumor margin does not increase the risk of recurrence in patients with T1-T2 well-differentiated thyroid cancer. Ann Surg Oncol. 2016;23:1446–51.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Lang BH, Shek TW, Wan KY. Does microscopically involved margin increase disease recurrence after curative surgery in papillary thyroid carcinoma? J Surg Oncol. 2016;113:635–9.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Kluijfhout WP, Drake FT, Pasternak JD, et al. Incidental positive lymph nodes in patients with papillary thyroid cancer is independently associated with recurrent disease. J Surg Oncol. 2017;116:275.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Adam MA, Pura J, Goffredo P, et al. Presence and number of lymph node metastases are associated with compromised survival for patients younger than age 45 years with papillary thyroid cancer. J Clin Oncol. 2015;33:2370–5.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Nixon IJ, Shaha AR. Implications of extra nodal extension in differentiated thyroid cancer. J Surg Oncol. 2017;116:459.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Nixon IJ, Wang LY, Palmer FL, et al. The impact of nodal status on outcome in older patients with papillary thyroid cancer. Surgery. 2014;156:137–46.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Yip J, Orlov S, Orlov D, et al. Predictive value of metastatic cervical lymph node ratio in papillary thyroid carcinoma recurrence. Head Neck. 2013;35:592–8.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Coburn MC, Wanebo HJ. Age correlates with increased frequency of high risk factors in elderly patients with thyroid cancer. Am J Surg. 1995;170:471–5.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90:6373–9.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Elisei R, Viola D, Torregrossa L, et al. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab. 2012;97:4390–8.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Kim TY, Kim WB, Rhee YS, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol. 2006;65:364–8.CrossRefGoogle Scholar
  30. 30.
    Li C, Lee KC, Schneider EB, Zeiger MA. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab. 2012;97:4559–70.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Fernandez IJ, Piccin O, Sciascia S, et al. Clinical significance of BRAF mutation in thyroid papillary cancer. Otolaryngol Head Neck Surg. 2013;148:919–25.CrossRefGoogle Scholar
  32. 32.
    Prescott JD, Sadow PM, Hodin RA, et al. BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence. Surgery. 2012;152:984–90.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Pasieka JL, Thompson NW, McLeod MK, et al. The incidence of bilateral well-differentiated thyroid cancer found at completion thyroidectomy. World J Surg. 1992;16:711–6; discussion 716–7.Google Scholar
  34. 34.
    De Jong SA, Demeter JG, Lawrence AM, Paloyan E. Necessity and safety of completion thyroidectomy for differentiated thyroid carcinoma. Surgery. 1992;112:734–7; discussion 737-9PubMedPubMedCentralGoogle Scholar
  35. 35.
    Untch BR, Palmer FL, Ganly I, et al. Oncologic outcomes after completion thyroidectomy for patients with well-differentiated thyroid carcinoma. Ann Surg Oncol. 2014;21:1374–8.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246:375–81. discussion 381–4.Google Scholar
  37. 37.
    Haigh PI, Urbach DR, Rotstein LE. Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. Ann Surg Oncol. 2005;12:81–9.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Mendelsohn AH, Elashoff DA, Abemayor E, St John MA. Surgery for papillary thyroid carcinoma: is lobectomy enough? Arch Otolaryngol Head Neck Surg. 2010;136:1055–61.CrossRefGoogle Scholar
  39. 39.
    Barney BM, Hitchcock YJ, Sharma P, et al. Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck. 2011;33:645–9.CrossRefGoogle Scholar
  40. 40.
    Adam MA, Pura J, Gu L, et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg. 2014;260:601–5; discussion 605-7CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Grant CS, Hay ID, Gough IR, et al. Local recurrence in papillary thyroid carcinoma: is extent of surgical resection important? Surgery. 1988;104:954–62.PubMedGoogle Scholar
  42. 42.
    Hay ID, Grant CS, Bergstralh EJ, et al. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery. 1998;124:958–64; discussion 964–6.Google Scholar
  43. 43.
    Nixon IJ, Ganly I, Patel SG, et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery. 2012;151:571–9.CrossRefGoogle Scholar
  44. 44.
    Vaisman F, Shaha A, Fish S, Michael Tuttle R. Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. Clin Endocrinol. 2011;75:112–9.CrossRefGoogle Scholar
  45. 45.
    Matsuzu K, Sugino K, Masudo K, et al. Thyroid lobectomy for papillary thyroid cancer: long-term follow-up study of 1,088 cases. World J Surg. 2014;38:68–79.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Kim SK, Park I, Woo JW, et al. Total thyroidectomy versus lobectomy in conventional papillary thyroid microcarcinoma: analysis of 8,676 patients at a single institution. Surgery. 2017;161:485–92.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Lang W, Borrusch H, Bauer L. Occult carcinomas of the thyroid. Evaluation of 1,020 sequential autopsies. Am J Clin Pathol. 1988;90:72–6.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Miyauchi A, Kudo T, Ito Y, et al. Estimation of the lifetime probability of disease progression of papillary microcarcinoma of the thyroid during active surveillance. Surgery. 2018;163:48–52.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Ito Y, Miyauchi A, Oda H. Low-risk papillary microcarcinoma of the thyroid: a review of active surveillance trials. Eur J Surg Oncol. 2017;44(3):307–15.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Carhill AA, Litofsky DR, Ross DS, et al. Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987–2012. J Clin Endocrinol Metab. 2015;100:3270–9.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Schvartz C, Bonnetain F, Dabakuyo S, et al. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J Clin Endocrinol Metab. 2012;97:1526–35.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Sawka AM, Brierley JD, Tsang RW, et al. An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin N Am. 2008;37:457–80. xCrossRefGoogle Scholar
  53. 53.
    Sacks W, Fung CH, Chang JT, et al. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid. 2010;20:1235–45.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Lamartina L, Durante C, Filetti S, Cooper DS. Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature. J Clin Endocrinol Metab. 2015;100:1748–61.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Strickland KC, Howitt BE, Marqusee E, et al. The impact of noninvasive follicular variant of papillary thyroid carcinoma on rates of malignancy for fine-needle aspiration diagnostic categories. Thyroid. 2015;25:987–92.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Lau RP, Paulsen JD, Brandler TC, et al. Impact of the reclassification of “noninvasive encapsulated follicular variant of papillary thyroid carcinoma” to “noninvasive follicular thyroid neoplasm with papillary-like nuclear features” on the Bethesda system for reporting thyroid cytopathology: a Large academic institution’s experience. Am J Clin Pathol. 2017;149(1):50–4.CrossRefGoogle Scholar
  57. 57.
    Tuttle RM, Haugen B, Perrier ND. Updated American Joint Committee on Cancer/tumor-node-metastasis staging system for differentiated and anaplastic thyroid cancer (eighth edition): what changed and why? Thyroid. 2017;27:751–6.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Ross DS, Litofsky D, Ain KB, et al. Recurrence after treatment of micropapillary thyroid cancer. Thyroid. 2009;19:1043–8.CrossRefGoogle Scholar
  59. 59.
    O'Connell K, Yen TW, Quiroz F, et al. The utility of routine preoperative cervical ultrasonography in patients undergoing thyroidectomy for differentiated thyroid cancer. Surgery. 2013;154:697–701; discussion 701–3.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Brito JP, Ito Y, Miyauchi A, Tuttle RM. A clinical framework to facilitate risk stratification when considering an active surveillance alternative to immediate biopsy and surgery in papillary microcarcinoma. Thyroid. 2016;26:144–9.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Rosario PW, Mourao GF, Calsolari MR. Apparently intrathyroid papillary thyroid carcinoma >1 and ≤4 cm: is the need for completion thyroidectomy common among patients submitted to lobectomy? Clin Endocrinol (Oxf). 2016;85(1):150–1.CrossRefGoogle Scholar
  62. 62.
    Kluijfhout WP, Pasternak JD, Lim J, et al. Frequency of high-risk characteristics requiring total thyroidectomy for 1-4 cm well-differentiated thyroid cancer. Thyroid. 2016;26:820–4.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Lang BH, Shek TW, Wan KY. The significance of unrecognized histological high-risk features on response to therapy in papillary thyroid carcinoma measuring 1-4 cm: implications for completion thyroidectomy following lobectomy. Clin Endocrinol. 2017;86:236–42.CrossRefGoogle Scholar
  64. 64.
    Vaisman F, Momesso D, Bulzico DA, et al. Thyroid lobectomy is associated with excellent clinical outcomes in properly selected differentiated thyroid cancer patients with primary tumors greater than 1 cm. J Thyroid Res. 2013;2013:398194.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Yeh MW. Moving towards perfection: avoiding unnecessary surgery, eliminating complications, and reducing costs. American Thyroid Association Meeting in Victoria BC. 2017.Google Scholar
  66. 66.
    Esnaola NF, Cantor SB, Sherman SI, et al. Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis. Surgery. 2001;130:921–30.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Shrime MG, Goldstein DP, Seaberg RM, et al. Cost-effective management of low-risk papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2007;133:1245–53.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Lang BH, Wong CKH. Lobectomy is a more cost-effective option than total thyroidectomy for 1 to 4 cm papillary thyroid carcinoma that do not possess clinically recognizable high-risk features. Ann Surg Oncol. 2016;23:3641–52.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Kluijfhout WP, Rotstein LE, Pasternak JD. Well-differentiated thyroid cancer: thyroidectomy or lobectomy? CMAJ. 2016;188:E517–20.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Razavi CR, Tufano RP, Russell JO. Completion thyroidectomy via the transoral endoscopic vestibular approach. Gland Surg. 2018;7:S77–9.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Anuwong A, Ketwong K, Jitpratoom P, et al. Safety and outcomes of the Transoral endoscopic thyroidectomy vestibular approach. JAMA Surg. 2017;153(1):21–7.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Division of Endocrinology, Diabetes and MetabolismThe Johns Hopkins School of MedicineBaltimoreUSA

Personalised recommendations